REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 25, No. 1S (2024)
http://www.veterinaria.org
Article Received: Revised: Accepted:

Incidence and Impact of Ventilator-Associated Pneumonia in ICU Patients with Severe Pneumonia and Respiratory Failure: A Prospective Study

Dr. Satakshi Manwani[1], Dr. Krishna Gopal Singh[2], Dr. Harsha Gupta[3], Dr. Yash Raj Gupta[4*], Dr. Kuldeep Singh[5], Dr. Rajdeep Paul[6]

[1,5&6] Assistant Professor, Department of Microbiology, Chirayu Medical College & Hospital, Bhopal, M.P.
[2]Associate Professor, Department of Respiratory Medicine, Chirayu Medical College & Hospital, Bhopal, M.P.
[3]Associate Professor, Department of Anesthesiology, Chirayu Medical College & Hospital, Bhopal, M.P.
[4]Junior Resident, Department of Internal Medicine, Chirayu Medical College & Hospital, Bhopal, M.P.

***Corresponding Author:** Dr. Yash Raj Gupta
*Email: dr.y.r.gupta@gmail.com

Abstract:
Ventilator-associated pneumonia (VAP) is a critical complication affecting intensive care unit (ICU) patients with severe pneumonia and respiratory failure, significantly impacting morbidity and mortality rates. This prospective study aims to investigate the incidence, clinical outcomes, and risk factors associated with VAP in this vulnerable patient population. Data were collected from ICU admissions at Tertiary Care Hospital in Central India between June 2023 and December 2023, focusing on patients diagnosed with severe pneumonia and requiring mechanical ventilation. The incidence of VAP, defined by clinical criteria and microbiological confirmation, was assessed alongside patient outcomes, including length of ICU stay, mortality rates, and antibiotic utilization. Multivariate analysis identified independent predictors of VAP occurrence and associated complications. Findings underscore the profound clinical implications of VAP in ICU settings, emphasizing the need for rigorous preventive strategies and optimized management protocols to improve patient outcomes.

Introduction: Ventilator-associated pneumonia (VAP) is a prevalent nosocomial infection among critically ill patients requiring mechanical ventilation in intensive care units (ICUs). It complicates the management of severe pneumonia and respiratory failure, posing substantial challenges due to its association with increased morbidity, mortality, and healthcare costs. The incidence of VAP varies widely, influenced by patient-specific factors, ICU practices, and antimicrobial resistance patterns. Early recognition and appropriate management are crucial to mitigate the impact of VAP on patient outcomes. This prospective study aims to explore the incidence, clinical impact, and risk factors associated with VAP specifically in ICU patients with severe pneumonia and respiratory failure at Chirayu Medical College & Hospital.

Methods: This prospective cohort study included ICU patients diagnosed with severe pneumonia and requiring mechanical ventilation, admitted to a Tertiary Care Hospital in Central India between June 2023 and December 2023. Data were collected prospectively from electronic health records, focusing on demographic characteristics, comorbidities, severity of illness scores, and microbiological profiles. VAP was diagnosed based on clinical criteria including new or progressive infiltrates on chest radiography, purulent respiratory secretions, fever, leukocytosis, and microbiological confirmation from lower respiratory tract specimens. Clinical outcomes such as ICU length of stay, duration of mechanical ventilation, mortality rates, and antibiotic utilization were analyzed. Multivariate logistic regression was performed to identify independent predictors of VAP occurrence and associated complications.

Results: Our study enrolled a total of 100 ICU patients, with 30 patients diagnosed with ventilator-associated pneumonia (VAP) and 70 patients without VAP (Non-VAP).

Table 1 summarizes the demographic and clinical characteristics of the study cohort. There were no significant differences in age (mean ± SD, VAP vs. Non-VAP: 65 ± 12 vs. 63 ± 11 years, p = 0.25) or gender distribution (Male/Female, VAP vs. Non-VAP: 18/12 vs. 45/25, p = 0.67) between the two groups. However, patients with VAP exhibited a significantly higher mean APACHE II score (23 ± 6 vs. 20 ± 5, p = 0.03*), indicating a greater severity of illness at ICU admission. Comorbidities such as diabetes, hypertension, chronic respiratory disease, and immunosuppression were comparable between VAP and Non-VAP groups.

Table 1: Demographic and Clinical Characteristics of ICU Patients

Characteristic	VAP Patients (n=30)	Non-VAP Patients (n=70)	p-value
Age (years, mean ± SD)	65 ± 12	63 ± 11	0.25
Gender (Male/Female)	18/12	45/25	0.67

APACHE II score (mean ± SD)	23 ± 6	20 ± 5	0.03*
Comorbidities (%)			
- Diabetes	12 (40%)	20 (29%)	0.32
- Hypertension	14 (47%)	25 (36%)	0.29
- Chronic Respiratory Disease	8 (27%)	10 (14%)	0.11
- Immunosuppression	5 (17%)	6 (9%)	0.22

***p < 0.05**

Table 2 presents the incidence and outcomes associated with VAP compared to Non-VAP patients. The incidence of VAP in our ICU cohort was 30%. Patients with VAP had significantly longer ICU length of stay (28 ± 10 days vs. 14 ± 6 days, $p < 0.001$*), prolonged duration of mechanical ventilation (20 ± 8 days vs. 10 ± 4 days, $p < 0.001$*), higher ICU mortality rate (50% vs. 14%, $p < 0.001$*), and increased antibiotic utilization (25 ± 9 days vs. 15 ± 6 days, $p < 0.001$*) compared to Non-VAP patients.

Table 2: Incidence and Outcomes of VAP

Outcome	VAP Patients (n=30)	Non-VAP Patients (n=70)	p-value
Incidence of VAP (%)	30%	-	-
ICU Length of Stay (days, mean ± SD)	28 ± 10	14 ± 6	<0.001*
Duration of Mechanical Ventilation (days, mean ± SD)	20 ± 8	10 ± 4	<0.001*
ICU Mortality Rate (%)	15 (50%)	10 (14%)	<0.001*
Antibiotic Utilization (days, mean ± SD)	25 ± 9	15 ± 6	<0.001*

***p < 0.05**

Table 3 provides an overview of the pathogens identified in VAP patients. The most common pathogens isolated were Pseudomonas aeruginosa (33%), Staphylococcus aureus (including MRSA, 27%), Klebsiella pneumoniae (20%), Acinetobacter baumannii (13%), and Escherichia coli (7%).

Table 3: Pathogens Identified in VAP Patients

Pathogen	Frequency (%)
Pseudomonas aeruginosa	10 (33%)
Staphylococcus aureus (MRSA)	8 (27%)
Klebsiella pneumoniae	6 (20%)
Acinetobacter baumannii	4 (13%)
Escherichia coli	2 (7%)



Lastly, Table 4 presents the results of multivariate analysis identifying risk factors associated with VAP. Factors such as higher APACHE II score (OR 1.15, 95% CI 1.04-1.26, $p = 0.01$*), prolonged duration of mechanical ventilation (OR 1.25, 95% CI 1.10-1.41, $p < 0.001$*), and previous antibiotic use (OR 1.20, 95% CI 1.05-1.37, $p = 0.008$*) were independently associated with increased odds of developing VAP.

Table 4: Multivariate Analysis of Risk Factors for VAP

Risk Factor	Odds Ratio (95% CI)	p-value

Age	1.02 (0.98-1.05)	0.27
APACHE II score	1.15 (1.04-1.26)	0.01*
Duration of Mechanical Ventilation	1.25 (1.10-1.41)	<0.001*
Comorbidities (Presence)	1.35 (0.89-2.03)	0.16
Previous Antibiotic Use	1.20 (1.05-1.37)	0.008*

***p < 0.05**

Discussion: Ventilator-associated pneumonia (VAP) remains a significant complication in critically ill patients, particularly those with severe pneumonia and respiratory failure. Our prospective study provides valuable insights into the epidemiology, risk factors, clinical outcomes, and microbiological profiles associated with VAP, contributing to the existing literature on this challenging nosocomial infection.

Comparison of Incidence and Risk Factors: The incidence of VAP in our study cohort was 30%, which is consistent with previous reports ranging from 10% to 30% in similar patient populations (1, 2). This incidence underscores the persistent challenge of VAP despite advances in ICU care and infection control measures. Our findings align with previous studies that have identified higher APACHE II scores and prolonged mechanical ventilation as significant risk factors for developing VAP (3, 4). The association between severity of illness at ICU admission (as indicated by APACHE II scores) and VAP incidence highlights the critical role of initial disease severity in predisposing patients to subsequent infections during their ICU stay.

Clinical Outcomes: Our study revealed several adverse clinical outcomes associated with VAP compared to non-VAP patients. Patients with VAP experienced significantly longer ICU length of stay (28 ± 10 days vs. 14 ± 6 days, $p < 0.001$*), prolonged duration of mechanical ventilation (20 ± 8 days vs. 10 ± 4 days, $p < 0.001$*), higher ICU mortality rate (50% vs. 14%, $p < 0.001$*), and increased antibiotic utilization (25 ± 9 days vs. 15 ± 6 days, $p < 0.001$*). These findings are consistent with meta-analyses and large-scale studies that have demonstrated worse outcomes among VAP patients, including higher mortality rates and increased healthcare costs (5, 6). The substantial impact of VAP on patient outcomes underscores the urgent need for effective preventive strategies and early management interventions aimed at reducing VAP-associated morbidity and mortality.

Microbiological Profile: In our study, the microbiological profile of VAP included predominantly multidrug-resistant pathogens such as Pseudomonas aeruginosa, Staphylococcus aureus (including MRSA), Klebsiella pneumoniae, Acinetobacter baumannii, and Escherichia coli. These findings are consistent with global trends reported in the literature, emphasizing the complexity and diversity of pathogens contributing to VAP (7, 8). The identification of these pathogens underscores the importance of targeted antibiotic therapy guided by local epidemiological data and antimicrobial resistance patterns to optimize treatment outcomes in VAP patients.

Comparative Analysis of Preventive Strategies: Effective prevention strategies are crucial in mitigating the burden of VAP. Our study highlights the need for multifaceted approaches tailored to the specific patient population and local epidemiological context. While bundled interventions and surveillance programs have shown promise in reducing VAP rates in some settings (9, 10), their implementation and efficacy can vary widely across healthcare institutions. Moreover, emerging strategies such as antimicrobial stewardship, oral care protocols, and elevation of the head of the bed have demonstrated varying success rates in reducing VAP incidence and improving patient outcomes (11, 12). Future research should focus on refining these strategies and exploring novel preventive measures to further enhance VAP prevention efforts.

Limitations and Future Directions: Our study has several limitations that warrant consideration. Firstly, the single-center design may limit the generalizability of our findings to other healthcare settings. Multicenter studies involving diverse patient populations are needed to validate our results and provide more robust evidence on the epidemiology and outcomes of VAP. Secondly, the observational nature of our study introduces potential biases, including selection bias and confounding variables that may influence the interpretation of results. Future research should incorporate randomized controlled trials and prospective cohort studies to strengthen the evidence base and clarify the causal relationships between risk factors and VAP development. Lastly, exploring the impact of novel therapies such as probiotics and selective digestive decontamination on VAP prevention represents a promising avenue for future investigation based on emerging evidence (13, 14).

Conclusion: In conclusion, our prospective study enhances understanding of the epidemiology, risk factors, clinical outcomes, and microbiological profiles associated with VAP in ICU patients with severe pneumonia and respiratory failure. By comparing our findings with existing literature, we underscore the significant impact of VAP on patient morbidity, mortality, and healthcare utilization. Addressing these challenges requires concerted efforts to implement effective preventive strategies and optimize management protocols tailored to local epidemiological contexts. Ultimately,

reducing the incidence of VAP and improving outcomes in critically ill patients remain crucial goals for enhancing ICU care delivery and patient safety.

References:

1. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171(4):388-416.
2. Melsen WG, Rovers MM, Groenwold RH, et al. Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis. 2013;13(8):665-671.
3. Jones RN, Nicasio AM, Davis TE, et al. Quality and antimicrobial resistance among gram-negative pulmonary pathogens in the intensive care unit: analysis of SMART surveillance program data for 2009. Clin Infect Dis. 2011;53 Suppl 2.
4. Smith RL, Meixler SM, Simberkoff MS. Excess mortality in critically ill patients with nosocomial bloodstream infections. Chest. 1991;100(6):164S-169S.
5. Patel N, Smith PB, Kudumu-Clavell M, et al. Predictors of mortality in adult patients with ventilator-associated pneumonia: a meta-analysis. Chest. 2013;144(2):341-348.
6. Nguyen LD, Viscogliosi E, Delhaes L. The lung mycobiome: an emerging field of the human respiratory microbiome. Front Microbiol. 2015;6:89.
7. Lee H, Yoon SH, Lee SY, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Infect Control. 2016;44(3).
8. Hranjec T, Rosenberger LH, Swenson B, et al. Aggressive versus conservative initiation of antimicrobial treatment in critically ill surgical patients with suspected intensive-care-unit-acquired infection: a quasi-experimental, before and after observational cohort study. Lancet Infect Dis. 2012;12(10):774-780.
9. Klompas M. Strategies to prevent ventilator-associated pneumonia in acute care hospitals: 2014 update. Curr Infect Dis Rep. 2014;16(12):446.
10. Muscedere J, Dodek P, Keenan S, et al. Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: prevention. J Crit Care. 2008;23(1):126-137.
11. Zilberberg MD, Shorr AF. Ventilator-associated pneumonia: the clinical pulmonary infection score as a surrogate for diagnostics and outcome. Clin Infect Dis. 2010;51 Suppl 1.
12. Dezfulian C, Shojania K, Collard HR, et al. Subglottic secretion drainage for preventing ventilator-associated pneumonia: a meta-analysis. Am J Med. 2005;118(1):11-18.
13. Manzanares W, Lemieux M, Langlois PL, et al. Probiotic and synbiotic therapy in critical illness: a systematic review and meta-analysis. Crit Care. 2016;20(1):262.
14. Silvestri L, van Saene HK, Casarin A, et al. Selective decontamination of the digestive tract reduces bacterial bloodstream infection and mortality in critically ill patients: systematic review of randomized, controlled trials. J Hosp Infect. 2007;65(3):187-203.